Bitcoin price today: gains to $120k, near record high on U.S. regulatory cheer
Vertex Pharmaceuticals (NASDAQ:VRTX), a $96 billion biotechnology company with a "GOOD" InvestingPro Financial Health score, saw its CEO and President Reshma Kewalramani report purchasing shares of the company’s common stock on August 6, 2025, in two separate transactions. The insider buying comes as the stock trades near its 52-week low, having declined over 15% in the past week.
The transactions, both classified as open market purchases, involved a total of 10,000 shares acquired at prices ranging from $389.08 to $389.95, resulting in a total value of $3.89 million. Specifically, 4,290 shares were bought at a weighted average price of $389.08 (ranging from $388.71 to $389.43), and 5,710 shares were purchased at a weighted average price of $389.95 (ranging from $389.72 to $390.53). According to InvestingPro, this insider purchase aligns with management’s recent share buyback activities.
Following these transactions, Kewalramani directly owns 115,968 shares of Vertex Pharmaceuticals. Based on InvestingPro analysis, the stock currently trades below its Fair Value, with analysts setting price targets ranging from $330 to $624.
In other recent news, Vertex Pharmaceuticals reported second-quarter 2025 total revenue of $2.96 billion, surpassing both Truist Securities’ estimate of $2.93 billion and the Street consensus of $2.91 billion. Despite this revenue beat, the company faced challenges with its pain pipeline, leading to several analysts adjusting their price targets. Canaccord Genuity lowered its price target to $411, citing mixed pipeline updates, while maintaining a Hold rating. Bernstein SocGen Group, however, increased its price target to $471, despite setbacks in the pain program, maintaining a Market Perform rating. Truist Securities reduced its price target to $490 due to Vertex’s dependence on cystic fibrosis treatments, yet kept a Buy rating. H.C. Wainwright also lowered its price target to $478 after Vertex’s NaV1.8 inhibitor failed to meet the primary endpoint in trials, while still maintaining a Buy rating. Stifel adjusted its price target to $455, noting that Vertex will not pursue a broad painful neuropathic pain label in upcoming trials. These developments reflect the mixed reactions from analysts regarding Vertex’s recent performance and future prospects.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.